{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:41:47Z","timestamp":1793155307726,"version":"4.5.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01799-2","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T02:16:47Z","timestamp":1777256207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming"],"prefix":"10.1186","volume":"19","author":[{"given":"Na","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Lei","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"3","key":"1799_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1799_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1799_CR3","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jaccao.2025.01.011","volume":"7","author":"F Fang","year":"2025","unstructured":"Fang F, Zhang X, Li J. Personalized Trastuzumab-Induced Cardiac Dysfunction Risk Stratification and Surveillance. JACC CardioOncol. 2025;7(3):216\u20138.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"1799_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66.","journal-title":"Nat Rev Dis Primers"},{"issue":"14","key":"1799_CR5","doi-asserted-by":"publisher","first-page":"11791","DOI":"10.3390\/ijms241411791","volume":"24","author":"JS Lee","year":"2023","unstructured":"Lee JS, et al. CDK4\/6 Inhibitor Resistance in Hormone Receptor-Positive Metastatic Breast Cancer: Translational Research, Clinical Trials, and Future Directions. Int J Mol Sci. 2023;24(14):11791.","journal-title":"Int J Mol Sci"},{"key":"1799_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.critrevonc.2019.05.001","volume":"139","author":"C Vernieri","year":"2019","unstructured":"Vernieri C, et al. Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. Crit Rev Oncol Hematol. 2019;139:53\u201366.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1799_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2020.23370","volume":"325","author":"X Wang","year":"2021","unstructured":"Wang X, et al. Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial. JAMA. 2021;325(1):50\u20138.","journal-title":"JAMA"},{"issue":"2","key":"1799_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, et al. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19(2):91\u2013113.","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"1799_CR9","doi-asserted-by":"publisher","first-page":"e172156","DOI":"10.1172\/JCI172156","volume":"133","author":"HL Chang","year":"2023","unstructured":"Chang HL, Schwettmann B, McArthur HL, Chan IS. Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response. J Clin Invest. 2023;133(18):e172156.","journal-title":"J Clin Invest"},{"issue":"8","key":"1799_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, et al. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22(8):641\u201361.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1799_CR11","first-page":"165","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72(2):165\u201382.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1799_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","volume":"16","author":"L Conilh","year":"2023","unstructured":"Conilh L, et al. Payload diversification: a key step in the development of antibody-drug conjugates. J Hematol Oncol. 2023;16(1):3.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1799_CR13","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","volume":"16","author":"LC Tsao","year":"2025","unstructured":"Tsao LC, et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat Commun. 2025;16(1):3167.","journal-title":"Nat Commun"},{"issue":"1","key":"1799_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"issue":"1","key":"1799_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12272-023-01479-6","volume":"47","author":"S Kumari","year":"2024","unstructured":"Kumari S, Raj S, Babu MA, Bhatti GK, Bhatti JS. Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions. Arch Pharm Res. 2024;47(1):40\u201365.","journal-title":"Arch Pharm Res"},{"issue":"3","key":"1799_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama K, et al. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024;21(3):203\u201323.","journal-title":"Nat Rev Clin Oncol"},{"issue":"19","key":"1799_CR17","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783\u201391.","journal-title":"N Engl J Med"},{"issue":"329","key":"1799_CR18","doi-asserted-by":"publisher","first-page":"329ra34","DOI":"10.1126\/scitranslmed.aad5653","volume":"8","author":"S Wang","year":"2016","unstructured":"Wang S, et al. Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. Sci Transl Med. 2016;8(329):329ra34.","journal-title":"Sci Transl Med"},{"issue":"3","key":"1799_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41590-018-0292-y","volume":"20","author":"M Liu","year":"2019","unstructured":"Liu M, et al. Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated \u2018don\u2019t-eat-me\u2019 signal. Nat Immunol. 2019;20(3):265\u201375.","journal-title":"Nat Immunol"},{"issue":"7831","key":"1799_CR20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41586-020-2851-2","volume":"586","author":"RA Fernandes","year":"2020","unstructured":"Fernandes RA, et al. Immune receptor inhibition through enforced phosphatase recruitment. Nature. 2020;586(7831):779\u201384.","journal-title":"Nature"},{"issue":"11","key":"1799_CR21","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423\u201337.","journal-title":"Nat Med"},{"issue":"28","key":"1799_CR22","doi-asserted-by":"publisher","first-page":"12133","DOI":"10.1021\/jacs.0c01928","volume":"142","author":"B Wang","year":"2020","unstructured":"Wang B, et al. Potent and Prolonged Innate Immune Activation by Enzyme-Responsive Imidazoquinoline TLR7\/8 Agonist Prodrug Vesicles. J Am Chem Soc. 2020;142(28):12133\u20139.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"1799_CR23","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41467-018-04225-5","volume":"9","author":"PA Burnouf","year":"2018","unstructured":"Burnouf PA, et al. Reversible glycosidic switch for secure delivery of molecular nanocargos. Nat Commun. 2018;9(1):1843.","journal-title":"Nat Commun"},{"issue":"2","key":"1799_CR24","first-page":"1365","volume":"13","author":"P Kadiyala","year":"2019","unstructured":"Kadiyala P, et al. High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme. ACS Nano. 2019;13(2):1365\u201384.","journal-title":"ACS Nano"},{"issue":"8","key":"1799_CR25","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-19-1409","volume":"10","author":"DY Torrejon","year":"2020","unstructured":"Torrejon DY, et al. Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. Cancer Discov. 2020;10(8):1140\u201357.","journal-title":"Cancer Discov"},{"issue":"4","key":"1799_CR26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41551-019-0360-0","volume":"3","author":"P Zhao","year":"2019","unstructured":"Zhao P, et al. Depletion of PD-1-positive cells ameliorates autoimmune disease. Nat Biomed Eng. 2019;3(4):292\u2013305.","journal-title":"Nat Biomed Eng"},{"issue":"5","key":"1799_CR27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12272-023-01447-0","volume":"46","author":"R Maiti","year":"2023","unstructured":"Maiti R, et al. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities. Arch Pharm Res. 2023;46(5):361\u201388.","journal-title":"Arch Pharm Res"},{"issue":"9","key":"1799_CR28","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/s41416-022-01876-6","volume":"127","author":"Z Dongye","year":"2022","unstructured":"Dongye Z, Li J, Wu Y. Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity. Br J Cancer. 2022;127(9):1584\u201394.","journal-title":"Br J Cancer"},{"issue":"16","key":"1799_CR29","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021;384(16):1529\u201341.","journal-title":"N Engl J Med"},{"issue":"15","key":"1799_CR30","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1200\/JCO.23.01409","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia A, et al. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol. 2024;42(15):1738\u201344.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1799_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nri.2017.46","volume":"17","author":"J Hou","year":"2017","unstructured":"Hou J, Greten TF, Xia Q. Immunosuppressive cell death in cancer. Nat Rev Immunol. 2017;17(6):401.","journal-title":"Nat Rev Immunol"},{"issue":"16","key":"1799_CR32","doi-asserted-by":"publisher","first-page":"e2417586122","DOI":"10.1073\/pnas.2417586122","volume":"122","author":"YF Chen","year":"2025","unstructured":"Chen YF, et al. SNX10 deficiency impairs sensitivity to anti-HER2 antibody-drug conjugates via altering HER2 trafficking in HER2-positive breast cancer. Proc Natl Acad Sci U S A. 2025;122(16):e2417586122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1799_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang R, et al. Antibody\u2013Drug Conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol. 2025;18(1):51.","journal-title":"J Hematol Oncol"},{"key":"1799_CR34","doi-asserted-by":"publisher","first-page":"921385","DOI":"10.3389\/fphar.2022.921385","volume":"13","author":"X Qi","year":"2022","unstructured":"Qi X, et al. Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study. Front Pharmacol. 2022;13:921385.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1799_CR35","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","volume":"122","author":"FW Hunter","year":"2020","unstructured":"Hunter FW, et al. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br J Cancer. 2020;122(5):603\u201312.","journal-title":"Br J Cancer"},{"issue":"6","key":"1799_CR36","doi-asserted-by":"publisher","first-page":"100668","DOI":"10.1016\/j.xcrm.2022.100668","volume":"3","author":"I Makhlin","year":"2022","unstructured":"Makhlin I, DeMichele A. Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer. Cell Rep Med. 2022;3(6):100668.","journal-title":"Cell Rep Med"},{"issue":"1","key":"1799_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41523-024-00711-w","volume":"10","author":"VM Khatri","year":"2024","unstructured":"Khatri VM, et al. Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases. NPJ Breast Cancer. 2024;10(1):100.","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"1799_CR38","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/s41401-024-01279-8","volume":"45","author":"HF Zong","year":"2024","unstructured":"Zong HF, et al. A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer. Acta Pharmacol Sin. 2024;45(8):1727\u201339.","journal-title":"Acta Pharmacol Sin"},{"key":"1799_CR39","doi-asserted-by":"crossref","unstructured":"Wang Y, Guo C, Li W. Artificial intelligence in antibody-drug conjugate development. Trends Pharmacol Sci; 2025.","DOI":"10.1016\/j.tips.2025.10.005"},{"key":"1799_CR40","doi-asserted-by":"publisher","first-page":"1591191","DOI":"10.3389\/fimmu.2025.1591191","volume":"16","author":"F Zhang","year":"2025","unstructured":"Zhang F, Li S. Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions. Front Immunol. 2025;16:1591191.","journal-title":"Front Immunol"},{"issue":"5","key":"1799_CR41","doi-asserted-by":"publisher","first-page":"105059","DOI":"10.1016\/j.esmoop.2025.105059","volume":"10","author":"J Wang","year":"2025","unstructured":"Wang J, et al. Novel TROP2 antibody-drug conjugates for treatment of HER2-negative metastatic breast cancer patients with brain metastases: a promising option. ESMO Open. 2025;10(5):105059.","journal-title":"ESMO Open"},{"issue":"8","key":"1799_CR42","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s41589-025-01950-z","volume":"21","author":"A Croitoru","year":"2025","unstructured":"Croitoru A, Orr AA, MacKerell AD Jr. Harnessing computational technologies to facilitate antibody-drug conjugate development. Nat Chem Biol. 2025;21(8):1138\u201347.","journal-title":"Nat Chem Biol"},{"issue":"3","key":"1799_CR43","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1039\/C6SC05149A","volume":"8","author":"N Gupta","year":"2017","unstructured":"Gupta N, et al. Development of a facile antibody-drug conjugate platform for increased stability and homogeneity. Chem Sci. 2017;8(3):2387\u201395.","journal-title":"Chem Sci"},{"issue":"20","key":"1799_CR44","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097\u2013108.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1799_CR45","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382(7):610\u201321.","journal-title":"N Engl J Med"},{"key":"1799_CR46","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1038\/s41591-025-03981-4","volume":"31","author":"S Modi","year":"2025","unstructured":"Modi S, Jacot W, Iwata H, et al. Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nat Med. 2025;31:4205\u20134213.","journal-title":"Nat Med"},{"issue":"1","key":"1799_CR47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41523-025-00829-5","volume":"11","author":"I Valle","year":"2025","unstructured":"Valle I, et al. Antibody\u2013drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives. npj Breast Cancer. 2025;11(1):102.","journal-title":"npj Breast Cancer"},{"issue":"10371","key":"1799_CR48","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105\u201317.","journal-title":"Lancet"},{"issue":"5","key":"1799_CR49","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1158\/2159-8290.CD-23-0838","volume":"14","author":"TP DiPeri","year":"2024","unstructured":"DiPeri TP, et al. Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer Discov. 2024;14(5):828\u201345.","journal-title":"Cancer Discov"},{"issue":"11","key":"1799_CR50","doi-asserted-by":"publisher","first-page":"9674","DOI":"10.3390\/ijms24119674","volume":"24","author":"R Khoury","year":"2023","unstructured":"Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R, et al. Mechanisms of Resistance to Antibody-Drug Conjugates. Int J Mol Sci. 2023;24(11):9674.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1799_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00280-025-04863-9","volume":"96","author":"X Ji","year":"2026","unstructured":"Ji X, et al. Recent advances in bispecific antibody-drug conjugates for breast cancer therapy. Cancer Chemother Pharmacol. 2026;96(1):15.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1799_CR52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/antib9030049","volume":"9","author":"J Cheng","year":"2020","unstructured":"Cheng J, Liang M, Carvalho MF, Tigue N, Faggioni R, Roskos LK, et al. Molecular mechanism of HER2 rapid internalization and redirected trafficking induced by anti-HER2 biparatopic antibody. Antibodies (Basel). 2020;9(3):49.","journal-title":"Antibodies (Basel)"},{"issue":"7","key":"1799_CR53","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/cancers15071987","volume":"15","author":"MF Mercogliano","year":"2023","unstructured":"Mercogliano MF, Bruni S, Mauro FL, Schillaci R, Elizalde PV, De Martino M. Emerging targeted therapies for HER2-positive breast cancer. Cancers (Basel). 2023;15(7):1987.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"1799_CR54","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1039\/D5CB00096C","volume":"6","author":"Q Xue","year":"2025","unstructured":"Xue Q, et al. A biparatopic HER2-targeting ADC constructed via site-specific glycan conjugation exhibits superior stability, safety, and efficacy. RSC Chem Biol. 2025;6(8):1284\u201396.","journal-title":"RSC Chem Biol"},{"issue":"10411","key":"1799_CR55","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10411):1423\u201333.","journal-title":"Lancet"},{"key":"1799_CR56","doi-asserted-by":"crossref","unstructured":"Xu B et al. Sacituzumab tirumotecan (SKB264\/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): results from the phase III OptiTROP-Breast01 study. 2024, American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2024.42.16_suppl.104"},{"key":"1799_CR57","doi-asserted-by":"publisher","first-page":"1683594","DOI":"10.3389\/fimmu.2025.1683594","volume":"16","author":"L Jiang","year":"2025","unstructured":"Jiang L, et al. The efficacy and safety of sacituzumab govitecan in the treatment of breast cancer: a systemic review and meta-analysis of emerging clinical data. Front Immunol. 2025;16:1683594.","journal-title":"Front Immunol"},{"issue":"3","key":"1799_CR58","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","volume":"43","author":"A Bardia","year":"2025","unstructured":"Bardia A, et al. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable\/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. J Clin Oncol. 2025;43(3):285\u201396.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1799_CR59","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1158\/1535-7163.MCT-24-0588","volume":"24","author":"WF Li","year":"2025","unstructured":"Li WF, et al. OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models. Mol Cancer Ther. 2025;24(2):163\u201375.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1799_CR60","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41698-024-00584-z","volume":"8","author":"DD Zhou","year":"2024","unstructured":"Zhou DD, et al. A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers. NPJ Precis Oncol. 2024;8(1):94.","journal-title":"NPJ Precis Oncol"},{"issue":"6Supplement","key":"1799_CR61","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1158\/1538-7445.AM2024-2616","volume":"84","author":"S Yao","year":"2024","unstructured":"Yao S, et al. Abstract 2616: BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts. Cancer Res. 2024;84(6Supplement):2616\u20132616.","journal-title":"Cancer Res"},{"issue":"2","key":"1799_CR62","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3390\/diagnostics15020232","volume":"15","author":"RO Y\u00fcceer","year":"2025","unstructured":"Y\u00fcceer RO, et al. Exploring the Prognostic Role of Trop-2, CD47, and CD163 Expression Levels on Survival Outcomes in Patients with Triple-Negative Breast Cancer. Diagnostics. 2025;15(2):232.","journal-title":"Diagnostics"},{"issue":"5","key":"1799_CR63","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc1609","volume":"5","author":"NE Hynes","year":"2005","unstructured":"Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341\u201354.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1799_CR64","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12943-018-0862-5","volume":"17","author":"X Li","year":"2018","unstructured":"Li X, et al. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer. Mol Cancer. 2018;17(1):113.","journal-title":"Mol Cancer"},{"issue":"18","key":"1799_CR65","doi-asserted-by":"publisher","first-page":"13726","DOI":"10.3390\/ijms241813726","volume":"24","author":"C Mark","year":"2023","unstructured":"Mark C, Lee JS, Cui X, Yuan Y. Antibody-Drug Conjugates in Breast Cancer: Current Status and Future Directions. Int J Mol Sci. 2023;24(18):13726.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1799_CR66","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13058-024-01859-w","volume":"26","author":"N Sinevici","year":"2024","unstructured":"Sinevici N, et al. A prospective study of HER3 expression pre and post neoadjuvant therapy of different breast cancer subtypes: implications for HER3 imaging therapy guidance. Breast Cancer Res. 2024;26(1):107.","journal-title":"Breast Cancer Res"},{"key":"1799_CR67","doi-asserted-by":"publisher","first-page":"1335252","DOI":"10.3389\/fimmu.2023.1335252","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, et al. The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy. Front Immunol. 2023;14:1335252.","journal-title":"Front Immunol"},{"issue":"2","key":"1799_CR68","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/cpt.3674","volume":"118","author":"L Li","year":"2025","unstructured":"Li L, et al. Exposure-Response Relationships in Patients with Non-Small-Cell Lung Cancer and Other Solid Tumors Treated with Patritumab Deruxtecan (HER3-DXd). Clin Pharmacol Ther. 2025;118(2):408\u201317.","journal-title":"Clin Pharmacol Ther"},{"issue":"36","key":"1799_CR69","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.1200\/JCO.23.00882","volume":"41","author":"IE Krop","year":"2023","unstructured":"Krop IE, et al. Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I\/II Trial. J Clin Oncol. 2023;41(36):5550\u201360.","journal-title":"J Clin Oncol"},{"key":"1799_CR70","doi-asserted-by":"publisher","first-page":"102113","DOI":"10.1016\/j.eclinm.2023.102113","volume":"62","author":"A D\u2019Arienzo","year":"2023","unstructured":"D\u2019Arienzo A, et al. Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations. EClinicalMedicine. 2023;62:102113.","journal-title":"EClinicalMedicine"},{"key":"1799_CR71","doi-asserted-by":"publisher","first-page":"1492782","DOI":"10.3389\/fimmu.2024.1492782","volume":"15","author":"MA Nix","year":"2024","unstructured":"Nix MA, et al. Identifying optimal tumor-associated antigen combinations with single-cell genomics to enable multi-targeting therapies. Front Immunol. 2024;15:1492782.","journal-title":"Front Immunol"},{"issue":"5","key":"1799_CR72","doi-asserted-by":"publisher","first-page":"101511","DOI":"10.1016\/j.xcrm.2024.101511","volume":"5","author":"L Xu","year":"2024","unstructured":"Xu L, et al. A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response. Cell Rep Med. 2024;5(5):101511.","journal-title":"Cell Rep Med"},{"issue":"3","key":"1799_CR73","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/cam4.1995","volume":"8","author":"S Watanabe","year":"2019","unstructured":"Watanabe S, et al. Targeting of the HER2\/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer. Cancer Med. 2019;8(3):1258\u201368.","journal-title":"Cancer Med"},{"issue":"318","key":"1799_CR74","doi-asserted-by":"publisher","first-page":"ra29","DOI":"10.1126\/scisignal.2005125","volume":"7","author":"JJ Tao","year":"2014","unstructured":"Tao JJ, et al. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal. 2014;7(318):ra29.","journal-title":"Sci Signal"},{"issue":"10","key":"1799_CR75","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","volume":"11","author":"JT Coates","year":"2021","unstructured":"Coates JT, et al. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. Cancer Discov. 2021;11(10):2436\u201345.","journal-title":"Cancer Discov"},{"issue":"7","key":"1799_CR76","doi-asserted-by":"publisher","first-page":"105330","DOI":"10.1016\/j.esmoop.2025.105330","volume":"10","author":"P Tarantino","year":"2025","unstructured":"Tarantino P, et al. Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer. ESMO Open. 2025;10(7):105330.","journal-title":"ESMO Open"},{"issue":"1","key":"1799_CR77","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41419-025-07657-2","volume":"16","author":"X Zhao","year":"2025","unstructured":"Zhao X, et al. PAK5 promotes the trastuzumab resistance by increasing HER2 nuclear accumulation in HER2-positive breast cancer. Cell Death Dis. 2025;16(1):323.","journal-title":"Cell Death Dis"},{"key":"1799_CR78","doi-asserted-by":"publisher","first-page":"217146","DOI":"10.1016\/j.canlet.2024.217146","volume":"599","author":"Y Chen","year":"2024","unstructured":"Chen Y, et al. ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance. Cancer Lett. 2024;599:217146.","journal-title":"Cancer Lett"},{"key":"1799_CR79","doi-asserted-by":"publisher","first-page":"101118","DOI":"10.1016\/j.drup.2024.101118","volume":"76","author":"L Wang","year":"2024","unstructured":"Wang L, et al. Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases. Drug Resist Updat. 2024;76:101118.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"1799_CR80","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-025-01752-9","volume":"18","author":"K Zhou","year":"2025","unstructured":"Zhou K, Liu X, Zhu H. Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies. J Hematol Oncol. 2025;18(1):96.","journal-title":"J Hematol Oncol"},{"issue":"Suppl","key":"1799_CR81","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.addr.2012.09.011","volume":"64","author":"RK Jain","year":"2012","unstructured":"Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2012;64(Suppl):353\u201365.","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"1799_CR82","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-17-0019","volume":"16","author":"F Li","year":"2017","unstructured":"Li F, et al. Tumor-Associated Macrophages Can Contribute to Antitumor Activity through Fc\u03b3R-Mediated Processing of Antibody-Drug Conjugates. Mol Cancer Ther. 2017;16(7):1347\u201354.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"1799_CR83","doi-asserted-by":"publisher","first-page":"105308","DOI":"10.1016\/j.esmoop.2025.105308","volume":"10","author":"R Nanda","year":"2025","unstructured":"Nanda R, et al. Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States. ESMO Open. 2025;10(6):105308.","journal-title":"ESMO Open"},{"issue":"6","key":"1799_CR84","doi-asserted-by":"publisher","first-page":"105294","DOI":"10.1016\/j.esmoop.2025.105294","volume":"10","author":"L Garc\u00eda-Est\u00e9vez","year":"2025","unstructured":"Garc\u00eda-Est\u00e9vez L, et al. The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study. ESMO Open. 2025;10(6):105294.","journal-title":"ESMO Open"},{"issue":"13","key":"1799_CR85","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.3390\/ijms26136523","volume":"26","author":"JY Jang","year":"2025","unstructured":"Jang JY, Kim SG, Choi JS, Park SH, Kim JH. Antibody-Drug conjugates powered by deruxtecan: Innovations and Challenges in oncology. Int J Mol Sci. 2025;26(13):6523.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"1799_CR86","doi-asserted-by":"publisher","first-page":"e39858","DOI":"10.1016\/j.heliyon.2024.e39858","volume":"10","author":"C Yang","year":"2024","unstructured":"Yang C, et al. IMM2520, a novel anti-CD47\/PD-L1 bispecific antibody for cancer immune therapy. Heliyon. 2024;10(21):e39858.","journal-title":"Heliyon"},{"issue":"5","key":"1799_CR87","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41419-024-06697-4","volume":"15","author":"Z Mai","year":"2024","unstructured":"Mai Z, et al. Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy. Cell Death Dis. 2024;15(5):307.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1799_CR88","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41698-025-01159-2","volume":"9","author":"Y Lu","year":"2025","unstructured":"Lu Y, et al. Leveraging artificial intelligence in antibody-drug conjugate development: from target identification to clinical translation in oncology. npj Precision Oncol. 2025;9(1):374.","journal-title":"npj Precision Oncol"},{"issue":"1","key":"1799_CR89","doi-asserted-by":"publisher","first-page":"10232","DOI":"10.1038\/s41467-024-54145-w","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, et al. Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications. Nat Commun. 2024;15(1):10232.","journal-title":"Nat Commun"},{"issue":"8","key":"1799_CR90","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3390\/nano10081613","volume":"10","author":"Y Yan","year":"2020","unstructured":"Yan Y, Ding H. pH-Responsive nanoparticles for cancer immunotherapy. Nanomaterials (Basel). 2020;10(8):1613.","journal-title":"Nanomaterials (Basel)"},{"key":"1799_CR91","doi-asserted-by":"publisher","first-page":"100633","DOI":"10.1016\/j.mtbio.2023.100633","volume":"20","author":"S Zeng","year":"2023","unstructured":"Zeng S, et al. Cell membrane-coated nanomaterials for cancer therapy. Mater Today Bio. 2023;20:100633.","journal-title":"Mater Today Bio"},{"issue":"2","key":"1799_CR92","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.apsb.2023.10.006","volume":"14","author":"S He","year":"2024","unstructured":"He S, et al. Dual-responsive supramolecular photodynamic nanomedicine with activatable immunomodulation for enhanced antitumor therapy. Acta Pharm Sin B. 2024;14(2):765\u201380.","journal-title":"Acta Pharm Sin B"},{"issue":"29","key":"1799_CR93","doi-asserted-by":"publisher","first-page":"e04860","DOI":"10.1002\/advs.202504860","volume":"12","author":"L Lei","year":"2025","unstructured":"Lei L, Dai W, Zhao J, Jiang A, Peng H, Jin Q, et al. A pH-Sensitive nanosized Covalent-Organic polymer for enhanced tumor photodynamic immunotherapy by hypoxia relief and stat3 inhibition. Adv Sci (Weinh). 2025;12(29):e04860.","journal-title":"Adv Sci (Weinh)"},{"issue":"11","key":"1799_CR94","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.3390\/biomedicines11113080","volume":"11","author":"S Balamkundu","year":"2023","unstructured":"Balamkundu S, Liu CF. Lysosomal-cleavable peptide linkers in antibody\u2013drug conjugates. Biomedicines. 2023;11(11):3080.","journal-title":"Biomedicines"},{"issue":"26","key":"1799_CR95","doi-asserted-by":"publisher","first-page":"e2100006","DOI":"10.1002\/smll.202100006","volume":"17","author":"F Zhang","year":"2021","unstructured":"Zhang F, et al. Coordination and Redox Dual-Responsive Mesoporous Organosilica Nanoparticles Amplify Immunogenic Cell Death for Cancer Chemoimmunotherapy. Small. 2021;17(26):e2100006.","journal-title":"Small"},{"issue":"11","key":"1799_CR96","doi-asserted-by":"publisher","first-page":"e003254","DOI":"10.1136\/jitc-2021-003254","volume":"9","author":"M Bazan-Peregrino","year":"2021","unstructured":"Bazan-Peregrino M, et al. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. J Immunother Cancer. 2021;9(11):e003254.","journal-title":"J Immunother Cancer"},{"issue":"7873","key":"1799_CR97","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583\u20139.","journal-title":"Nature"},{"issue":"1","key":"1799_CR98","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41698-025-01159-2","volume":"9","author":"Y Lu","year":"2025","unstructured":"Lu Y, et al. Leveraging artificial intelligence in antibody-drug conjugate development: from target identification to clinical translation in oncology. NPJ Precis Oncol. 2025;9(1):374.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"1799_CR99","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41592-020-01033-y","volume":"18","author":"V Marx","year":"2021","unstructured":"Marx V. Method of the Year: spatially resolved transcriptomics. Nat Methods. 2021;18(1):9\u201314.","journal-title":"Nat Methods"},{"issue":"10","key":"1799_CR100","doi-asserted-by":"publisher","first-page":"e765","DOI":"10.1002\/mco2.765","volume":"5","author":"N Wang","year":"2020","unstructured":"Wang N, et al. Next-generation spatial transcriptomics: unleashing the power to gear up translational oncology. MedComm. 2020;5(10):e765. 2024.","journal-title":"MedComm"},{"issue":"1","key":"1799_CR101","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","volume":"25","author":"EJ Topol","year":"2019","unstructured":"Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44\u201356.","journal-title":"Nat Med"},{"issue":"1","key":"1799_CR102","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s12967-025-06371-z","volume":"23","author":"S Shen","year":"2025","unstructured":"Shen S, et al. From virtual to reality: innovative practices of digital twins in tumor therapy. J Transl Med. 2025;23(1):348.","journal-title":"J Transl Med"},{"issue":"5","key":"1799_CR103","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315\u201337.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"1799_CR104","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.tips.2025.10.005","volume":"46","author":"Y Wang","year":"2025","unstructured":"Wang Y, Guo C, Li W. Artificial intelligence in antibody-drug conjugate development. Trends Pharmacol Sci. 2025;46(12):1209\u201323.","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"1799_CR105","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cac2.12387","volume":"43","author":"YF Chen","year":"2023","unstructured":"Chen YF, et al. Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. Cancer Commun (Lond). 2023;43(3):297\u2013337.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"1799_CR106","doi-asserted-by":"publisher","first-page":"22242","DOI":"10.1038\/s41598-021-01473-2","volume":"11","author":"M Kai","year":"2021","unstructured":"Kai M, et al. A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. Sci Rep. 2021;11(1):22242.","journal-title":"Sci Rep"},{"issue":"1","key":"1799_CR107","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41523-025-00842-8","volume":"11","author":"LA Huppert","year":"2025","unstructured":"Huppert LA, et al. Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer. NPJ Breast Cancer. 2025;11(1):130.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"1799_CR108","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","volume":"9","author":"A Bartolomucci","year":"2025","unstructured":"Bartolomucci A, et al. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. NPJ Precis Oncol. 2025;9(1):84.","journal-title":"NPJ Precis Oncol"},{"key":"1799_CR109","doi-asserted-by":"publisher","first-page":"115161","DOI":"10.1016\/j.colsurfb.2025.115161","volume":"257","author":"X Yao","year":"2026","unstructured":"Yao X, et al. Antibody-drug conjugates (ADCs): Smart Missiles targeting cancer therapy. Colloids Surf B. 2026;257:115161.","journal-title":"Colloids Surf B"},{"key":"1799_CR110","doi-asserted-by":"publisher","first-page":"103830","DOI":"10.1016\/j.breast.2024.103830","volume":"78","author":"L Sun","year":"2024","unstructured":"Sun L, et al. Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes. Breast. 2024;78:103830.","journal-title":"Breast"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01799-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01799-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01799-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T11:02:28Z","timestamp":1780830148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01799-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":110,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1799"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01799-2","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"13 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript is a review article and does not involve any original studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This review contains no individual patient data, images, or identifying information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}